Jason H Karnes1, Yan Gong, Michael A Pacanowski, Caitrin W McDonough, Meghan J Arwood, Taimour Y Langaee, Carl J Pepine, Julie A Johnson, Rhonda M Cooper-Dehoff. 1. aDepartment of Medicine, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee bDepartment of Pharmacotherapy and Translational Research cDepartment of Pharmacotherapy and Translational Research, Center for Pharmacogenomics dDepartment of Medicine, Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida eOffice of Clinical Pharmacology, Food and Drug Administration, Silver Spring, Maryland, USA.
Abstract
OBJECTIVE: Thiazide diuretics have been associated with increased risk for new onset diabetes (NOD), but pharmacogenetic markers of thiazide-induced NOD are not well studied. Single nucleotide polymorphisms (SNPs) in the transcription factor 7-like 2 gene (TCF7L2) represent the strongest and most reproducible genetic associations with diabetes. We investigated the association of tag SNPs in TCF7L2 with thiazide-induced NOD. METHODS: We identified cases that developed NOD and age, sex, and race/ethnicity-matched controls from the INternational VErapamil SR-Trandolapril STudy (INVEST). INVEST compared cardiovascular outcomes between two antihypertensive treatment strategies in ethnically diverse patients with hypertension and coronary artery disease. We genotyped 101 TCF7L2 tag SNPs and used logistic regression to test for pharmacogenetic (SNP×hydrochlorothiazide treatment) interactions. Permuted interaction P values were corrected with the PACT test and adjusted for diabetes-related variables. RESULTS: In INVEST whites, we observed three TCF7L2 SNPs with significant SNP×treatment interactions for NOD. The strongest pharmacogenetic interaction was observed for rs7917983 [synergy index 3.37 (95% CI 1.72-6.59), P=5.0×10, PACT=0.03], which was associated with increased NOD risk in hydrochlorothiazide-treated patients [odds ratio 1.53 (1.04-2.25), P=0.03] and decreased NOD risk in non hydrochlorothiazide-treated patients [odds ratio 0.48 (0.27-0.86), P=0.02]. The TCF7L2 SNP rs4506565, previously associated with diabetes, showed a similar, significant pharmacogenetic association. CONCLUSION: Our results suggest that hydrochlorothiazide treatment is an environmental risk factor that increases diabetes risk beyond that attributed to TCF7L2 variation in white, hypertensive patients. Further study and replication of our results is needed to confirm pharmacogenetic influences of TCF7L2 SNPs on thiazide-induced NOD.
OBJECTIVE:Thiazide diuretics have been associated with increased risk for new onset diabetes (NOD), but pharmacogenetic markers of thiazide-induced NOD are not well studied. Single nucleotide polymorphisms (SNPs) in the transcription factor 7-like 2 gene (TCF7L2) represent the strongest and most reproducible genetic associations with diabetes. We investigated the association of tag SNPs in TCF7L2 with thiazide-induced NOD. METHODS: We identified cases that developed NOD and age, sex, and race/ethnicity-matched controls from the INternational VErapamil SR-Trandolapril STudy (INVEST). INVEST compared cardiovascular outcomes between two antihypertensive treatment strategies in ethnically diverse patients with hypertension and coronary artery disease. We genotyped 101 TCF7L2 tag SNPs and used logistic regression to test for pharmacogenetic (SNP×hydrochlorothiazide treatment) interactions. Permuted interaction P values were corrected with the PACT test and adjusted for diabetes-related variables. RESULTS: In INVEST whites, we observed three TCF7L2 SNPs with significant SNP×treatment interactions for NOD. The strongest pharmacogenetic interaction was observed for rs7917983 [synergy index 3.37 (95% CI 1.72-6.59), P=5.0×10, PACT=0.03], which was associated with increased NOD risk in hydrochlorothiazide-treated patients [odds ratio 1.53 (1.04-2.25), P=0.03] and decreased NOD risk in non hydrochlorothiazide-treated patients [odds ratio 0.48 (0.27-0.86), P=0.02]. The TCF7L2 SNP rs4506565, previously associated with diabetes, showed a similar, significant pharmacogenetic association. CONCLUSION: Our results suggest that hydrochlorothiazide treatment is an environmental risk factor that increases diabetes risk beyond that attributed to TCF7L2 variation in white, hypertensivepatients. Further study and replication of our results is needed to confirm pharmacogenetic influences of TCF7L2 SNPs on thiazide-induced NOD.
Authors: Alkes L Price; Nick J Patterson; Robert M Plenge; Michael E Weinblatt; Nancy A Shadick; David Reich Journal: Nat Genet Date: 2006-07-23 Impact factor: 38.330
Authors: Donna M Lehman; Kelly J Hunt; Robin J Leach; Jeanette Hamlington; Rector Arya; Hanna E Abboud; Ravindranath Duggirala; John Blangero; Harald H H Göring; Michael P Stern Journal: Diabetes Date: 2007-02 Impact factor: 9.461
Authors: Laura J Scott; Lori L Bonnycastle; Cristen J Willer; Andrew G Sprau; Anne U Jackson; Narisu Narisu; William L Duren; Peter S Chines; Heather M Stringham; Michael R Erdos; Timo T Valle; Jaakko Tuomilehto; Richard N Bergman; Karen L Mohlke; Francis S Collins; Michael Boehnke Journal: Diabetes Date: 2006-09 Impact factor: 9.461
Authors: S C Elbein; W S Chu; S K Das; A Yao-Borengasser; S J Hasstedt; H Wang; N Rasouli; P A Kern Journal: Diabetologia Date: 2007-06-20 Impact factor: 10.122
Authors: E J Parra; E Cameron; L Simmonds; A Valladares; P McKeigue; M Shriver; N Wacher; J Kumate; R Kittles; M Cruz Journal: Clin Genet Date: 2007-04 Impact factor: 4.438
Authors: Steve E Humphries; David Gable; Jackie A Cooper; Helen Ireland; Jeffrey W Stephens; Steven J Hurel; Ka Wah Li; Jutta Palmen; Michelle A Miller; Francesco P Cappuccio; Robert Elkeles; Ian Godsland; George J Miller; Philippa J Talmud Journal: J Mol Med (Berl) Date: 2006-12 Impact factor: 4.599
Authors: Stéphane Cauchi; Younes El Achhab; Hélène Choquet; Christian Dina; Franz Krempler; Raimund Weitgasser; Chakib Nejjari; Wolfgang Patsch; Mohamed Chikri; David Meyre; Philippe Froguel Journal: J Mol Med (Berl) Date: 2007-05-03 Impact factor: 5.606
Authors: Eleftheria Zeggini; Michael N Weedon; Cecilia M Lindgren; Timothy M Frayling; Katherine S Elliott; Hana Lango; Nicholas J Timpson; John R B Perry; Nigel W Rayner; Rachel M Freathy; Jeffrey C Barrett; Beverley Shields; Andrew P Morris; Sian Ellard; Christopher J Groves; Lorna W Harries; Jonathan L Marchini; Katharine R Owen; Beatrice Knight; Lon R Cardon; Mark Walker; Graham A Hitman; Andrew D Morris; Alex S F Doney; Mark I McCarthy; Andrew T Hattersley Journal: Science Date: 2007-04-26 Impact factor: 47.728
Authors: Sonal Singh; Caitrin W McDonough; Yan Gong; Wael A Alghamdi; Meghan J Arwood; Salma A Bargal; Leanne Dumeny; Wen-Yi Li; Mai Mehanna; Bradley Stockard; Guang Yang; Felipe A de Oliveira; Natalie C Fredette; Mohamed H Shahin; Kent R Bailey; Amber L Beitelshees; Eric Boerwinkle; Arlene B Chapman; John G Gums; Stephen T Turner; Rhonda M Cooper-DeHoff; Julie A Johnson Journal: J Am Heart Assoc Date: 2018-03-09 Impact factor: 5.501
Authors: S-W Chang; C W McDonough; Y Gong; T A Johnson; T Tsunoda; E R Gamazon; M A Perera; A Takahashi; T Tanaka; M Kubo; C J Pepine; J A Johnson; R M Cooper-DeHoff Journal: Pharmacogenomics J Date: 2016-09-27 Impact factor: 3.550